Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Common Stock (Tables)

Common Stock (Tables)

3 Months Ended

Mar. 31, 2013

Components of stock-based compensation expense

The following table summarizes the stock-based compensation expense from awards, including stock options and restricted Common Stock awards to employees and non-employees, compensation expense for the ESPP and warrants to non-employees for the three months ended March 31, 2013 and 2012, and from the period June 28, 2006 (date of inception) to date.


	For the three months ended March 31,				Period from June 28, 2006 (date of inception) to March 31,
($ in thousands)	2013		2012		2013
Employee awards	$	972	$	313	$	4,178
Non-employee awards		434		445		3,847
Non-employee warrants		117		116		1,010

Total stock-based compensation expense	$	1,523	$	874	$	9,035

Summary of stock option activity

The following table summarizes stock option activity:


	Outstanding Options							Weighted Average Remaining Contractual Life (in years)
($ in thousands except per share amounts)	Number of Shares			Weighted Average Exercise Price		Total Weighted Average Intrinsic Value		Weighted Average Remaining Contractual Life (in years)
At December 31, 2012		2,519,070		$	3.37	$	2,860		8.5
Options granted		1,771,590			5.66
Options exercised		(193,490	)		1.37
Options cancelled		—

At March 31, 2013		4,097,170		$	4.46	$	21,564		8.97

Options vested and expected to vest		4,097,170		$	4.46	$	21,564		8.97
Options vested and exercisable		857,053		$	2.75	$	5,976		8.05